# Medicines and Healthcare products Regulatory Agency

CERTIFICATE NUMBER: UK MIA(IMP) 17696 Insp GMP/IMP 17696/36548-0012[I]

CERTIFICATE OF GMP COMPLIANCE OF A MANUFACTURER (1),(2)

## Part 1

Issued following an inspection in accordance with:

Part 6 of The Medicines for Human Use (Clinical Trials) Regulations 2004 (SI 2004/1031)

The competent authority of United Kingdom confirms the following:

The Manufacturer: COBRA BIOLOGICS LIMITED

Site address: COBRA BIOLOGICS LIMITED, STEPHENSON BUILDING, THE SCIENCE PARK, KEELE, ST5 5SP, UNITED KINGDOM

Has been inspected under the national inspection programme in connection with manufacturing authorisation no. UK MIA(IMP) 17696 in accordance with Part 6 of The Medicines for Human Use (Clinical Trials) Regulations 2004 (SI 2004/1031)

From the knowledge gained during inspection of this manufacturer, the latest of which was conducted on 16/12/2020, it is considered that it complies with

• The principles and guidelines of Good Manufacturing Practice laid down in Regulation B17 of the Human Medicines Regulations 2012 (as amended)

This certificate reflects the status of the manufacturing site at the time of the inspection noted above and should not be relied upon to reflect the compliance status if more than three years have elapsed since the date of that inspection. However, this period of validity may be reduced or extended using regulatory risk management principles by an entry in the Restrictions or Clarifying remarks field. This certificate is valid only when presented with all pages and both Parts 1 and 2. The authenticity of this certificate may be verified in MHRA-GMDP. If it does not appear, please contact the issuing authority.

- (1) Guidance on the interpretation of this template can be found in the Help menu of MHRA-GMDP database.
- (2) These requirements fulfil the GMP recommendations of WHO.

## Part 2

#### **Human Investigational Medicinal Products**

#### 1. MANUFACTURING OPERATIONS

- [ 1.1 ] Sterile Investigational Medicinal Products
- [ 1.1.1 ] Aseptically prepared (processing operations for the following dosage forms)
- [1.1.1.4] Small volume liquids
- [ 1.2 ] Non-sterile investigational medicinal products

[ 1.2.1 ] Non-Sterile Products (processing operations for the following dosage forms) [ 1.2.1.6 ] Liquids for internal use [ 1.2.1.17 ] Other non-sterile medicinal products Manufacture of low bioburden bulk drug substance solutions. [ 1.3 ] Biological investigational medicinal products [ 1.3.1 ] Biological medicinal products [1.3.1.2] Immunological products [1.3.1.4] Gene therapy products [ 1.3.1.5 ] Biotechnology products [ 1.3.1.8 ] Other biological medicinal products Antibodies, antibody conjugates Live microbial products; Therapeutic Virus; Plant extracted materia [ 1.4 ] Other products or manufacturing activity [ 1.4.2 ] Sterilisation of active substances/excipients/finished products: [ 1.4.2.1 ] Filtration [ 1.4.2.3 ] Moist heat [ 1.6 ] Quality control testing [ 1.6.2 ] Microbiological: non-sterility [1.6.3] Chemical/Physical [1.6.4] Biological 2. IMPORTATION OF MEDICINAL PRODUCTS [ 2.1 ] Quality control testing of imported medicinal products [2.1.2] Microbiological: non-sterility [2.1.3] Chemical/Physical [2.1.4] Biological [ 2.2 ] Batch certification of imported medicinal products [2.2.1] Sterile Products [2.2.1.1] Aseptically prepared [ 2.2.1.2 ] Terminally sterilised [ 2.2.2 ] Non-sterile products [ 2.2.3 ] Biological medicinal products [2.2.3.2] Immunological products

[2.2.3.3] Cell therapy products

[2.2.3.4] Gene therapy products

[2.2.3.5] Biotechnology products

[ 2.2.3.6 ] Human or animal extracted products

[ 2.2.3.8 ] Other biological medicinal products

Antibodies, antibody conjugates Live microbial products; Therapeutic Virus; Plant extracted materia

26/08/2021 Name and signature of the authorised person of the Competent Authority of United Kingdom

Confidential

Medicines and Healthcare products Regulatory Agency

Tel: Confidential